CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study

E-ISSN： 1526-4610|58|1|78-87

ISSN： 0017-8748

Source： HEADACHE, Vol.58, Iss.1, 2018-01, pp. : 78-87

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Predictors of response to onabotulinumtoxin A in chronic migraine

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25, Iss. 3, 2018-03 ,pp. : e40-e40

John Wiley & Sons Inc

Access to resources Recommend Favorite

OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 25, Iss. 2, 2018-02 ,pp. : 411-416

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Chronic Migraine with Intramuscular Pericranial Injections of Onabotulinumtoxin A

Recent Patents on CNS Drug Discovery, Vol. 9, Iss. 3, 2014-12 ,pp. : 181-192

Bentham Science Publishers

Access to resources Recommend Favorite

Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine

HEADACHE, Vol. 55, Iss. 9, 2015-10 ,pp. : 1218-1224

John Wiley & Sons Inc

Access to resources Recommend Favorite

The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK

By Batty Anthony J.

Journal of Medical Economics, Vol. 16, Iss. 7, 2013-07 ,pp. : 877-887

Informa Healthcare

Access to resources Recommend Favorite